Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,151JPY
16 Jul 2019
Change (% chg)

¥-22 (-0.36%)
Prev Close
¥6,173
Open
¥6,150
Day's High
¥6,180
Day's Low
¥6,106
Volume
534,200
Avg. Vol
1,062,519
52-wk High
¥7,796
52-wk Low
¥5,550

Latest Key Developments (Source: Significant Developments)

Shionogi & Co Adjusts Conversion Value For Euro-Yen Denominated Convertible Bonds Maturing In 2019
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Shionogi & Co Ltd <4507.T>::DECIDED TO ADJUST CONVERSION VALUE FOR EURO-YEN DENOMINATED CONVERTIBLE BONDS MATURING IN 2019.CONVERSION VALUE AFTER ADJUSTMENT IS 4,100.3 YEN.  Full Article

Shionogi & Co Ltd - Purchased All Outstanding Shares Of Pionnier Following Conclusion Of Latest Joint Study
Thursday, 13 Jun 2019 

Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD - PURCHASED ALL OUTSTANDING SHARES OF PIONNIER FOLLOWING CONCLUSION OF LATEST JOINT STUDY.  Full Article

BRIEF-Roche Says Xofluza Is Effective At Preventing Influenza
Tuesday, 4 Jun 2019 

Corrects spelling of Roche drug in headline to Xofluza:PHASE III STUDY SHOWED XOFLUZA (BALOXAVIR MARBOXIL) IS EFFECTIVE AT PREVENTING INFLUENZA INFECTION.COMPARED WITH PLACEBO, XOFLUZA TREATMENT SIGNIFICANTLY REDUCED LIKELIHOOD OF PEOPLE DEVELOPING FLU AFTER EXPOSURE TO INFECTED HOUSEHOLD MEMBER.PHASE III BLOCKSTONE STUDY, CONDUCTED BY SHIONOGI, MET ITS PRIMARY ENDPOINT.  Full Article

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics
Thursday, 7 Mar 2019 

March 7 (Reuters) - Shionogi & Co Ltd <4507.T>::AKILI AND SHIONOGI ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE DIGITAL THERAPEUTICS IN KEY ASIAN MARKETS.AKILI- CO, SHIONOGI ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE DIGITAL THERAPEUTICS IN KEY ASIAN MARKETS.AKILI INTERACTIVE- UPFRONT AND POTENTIAL MILESTONE PAYMENTS FOR JAPAN AND TAIWAN COMMERCIALIZATION VALUED UP TO $125 MILLION.AKILI INTERACTIVE- AKILI WILL RECEIVE SUBSTANTIAL ROYALTIES ON SALES OF THE PRODUCTS IN JAPAN AND TAIWAN.  Full Article

Genentech Announces FDA Approval Of Xofluza For Influenza
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Roche Holding AG ::GENENTECH ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR INFLUENZA.GENENTECH SAYS FDA APPROVED XOFLUZA (BALOXAVIR MARBOXIL) FOR TREATMENT OF ACUTE, UNCOMPLICATED INFLUENZA, OR FLU, IN PEOPLE 12 YEARS OF AGE AND OLDER.GENENTECH - ROCHE HOLDS WORLDWIDE RIGHTS TO XOFLUZA EXCLUDING JAPAN AND TAIWAN, WHICH WILL BE RETAINED EXCLUSIVELY BY SHIONOGI & CO., LTD.  Full Article

Shionogi signs license agreement with Rohto Pharmaceutical
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it signed license agreement with Rohto Pharmaceutical Co Ltd <<<4527.T>>>, regarding exclusive development and sale of regeneration medicine product candidates ADR-001 in Japan .  Full Article

GlaxoSmithKline Says Gets Positive CHMP Opinion For Juluca In Europe
Friday, 23 Mar 2018 

March 23 (Reuters) - GlaxoSmithKline Plc ::VIIV - CHMP POSITIVE OPINION FOR JULUCA IN EUROPE.‍VIIV HEALTHCARE GAINS CHMP POSITIVE OPINION FOR JULUCA (DOLUTEGRAVIR/RILPIVIRINE) IN EUROPE​.FINAL EC DECISION ON EUROPEAN APPROVAL FOR DOLUTEGRAVIR/RILPIVIRINE IS ANTICIPATED TOWARDS END OF Q2 OF 2018.  Full Article

GSK Says ViiV Healthcare Reports Positive Dolutegravir Data
Monday, 5 Mar 2018 

March 5 (Reuters) - Glaxosmithkline Plc ::GLAXOSMITHKLINE PLC - VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS.GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WHEN ADMINISTERED AT 50MG TWICE-DAILY WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, WAS EFFECTIVE.GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY.  Full Article

Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI ANNOUNCES FDA NEW DRUG APPLICATION (NDA) AND EMA MARKETING AUTHORIZATION APPLICATION (MAA) ACCEPTANCES FOR LUSUTROMBOPAG (S-888711).SHIONOGI & CO LTD - PRESCRIPTION DRUG USER FEE ACT DATE FOR AN FDA DECISION FOR LUSUTROMBOPAG IS AUGUST 26, 2018.  Full Article

Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada.The United States case is filed in the U.S. District Court for the District of Delaware and the patent is U.S patent No. 8,129,385.The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282..  Full Article

CORRECTED-UPDATE 2-GSK's two-drug HIV Dovato treatment meets main goal in study (July 10)

July 10 GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.